Revvity (RVTY, Financial) has unveiled three new Mimix reference standards aimed at enhancing in vitro diagnostics (IVD). These standards are tailored for use with next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) assays. They focus on detecting somatic mutations in genomic DNA (gDNA) from human samples.
Developed from cell lines, these reference standards adhere to U.S. Food and Drug Administration (FDA) regulatory requirements. This ensures that laboratories can seamlessly incorporate them into their current workflows, thereby supporting the monitoring of test performance and assay variation. Additionally, these standards contribute to identifying increases in both random and systemic errors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Revvity Inc (RVTY, Financial) is $126.06 with a high estimate of $185.00 and a low estimate of $90.00. The average target implies an upside of 39.42% from the current price of $90.42. More detailed estimate data can be found on the Revvity Inc (RVTY) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, Revvity Inc's (RVTY, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Revvity Inc (RVTY, Financial) in one year is $118.55, suggesting a upside of 31.11% from the current price of $90.42. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Revvity Inc (RVTY) Summary page.
RVTY Key Business Developments
Release Date: April 28, 2025
- Organic Growth: 4% in Q1 2025.
- Adjusted EPS: $1.01, above expectations of $0.93 to $0.95.
- Free Cash Flow Conversion: 97% of adjusted net income.
- Share Repurchase: $154 million worth of shares in Q1.
- Outstanding Share Count: 119.4 million at quarter end.
- Diagnostics Organic Growth: 5% in Q1 2025.
- Signals Software Business Growth: Over 20% organic growth in Q1.
- Revenue: $665 million in Q1 2025.
- Adjusted Operating Margins: 25.6% in Q1 2025.
- Net Debt to Adjusted EBITDA Leverage Ratio: 2.4x.
- Adjusted Tax Rate: 19.5% in Q1 2025.
- Full Year Organic Growth Outlook: 3% to 5%.
- Full Year Adjusted EPS Outlook: $4.90 to $5.00.
- Second Quarter Revenue Outlook: $700 million to $715 million.
- Second Quarter Adjusted EPS Outlook: $1.13 to $1.15.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Revvity Inc (RVTY, Financial) achieved a solid 4% organic growth in the first quarter, aligning with expectations despite a challenging macroeconomic environment.
- The company reported an adjusted EPS of $1.01, surpassing the expected range of $0.93 to $0.95.
- Revvity Inc (RVTY) demonstrated strong cash flow management with a 97% free cash flow conversion of adjusted net income and repurchased $154 million worth of shares.
- The Diagnostics segment grew 5% organically, driven by strong demand and resilience against macroeconomic changes.
- The Signals software business showed impressive performance with over 20% organic growth in the first quarter, with expectations for continued strong growth.
Negative Points
- Revvity Inc (RVTY) faced unforeseen demand fluctuations from US academic customers, impacting life science instruments and potentially limiting organic growth.
- The company anticipates a 60 basis point negative impact on adjusted operating margins due to tariff-related pressures.
- There is ongoing pressure on the Life Science Solutions segment, particularly in instrumentation, due to academic funding uncertainties.
- Revvity Inc (RVTY) expects slower demand from academic customers to persist, impacting overall growth projections.
- The company is navigating a dynamic tariff situation, which could have resulted in a $135 million gross impact on adjusted operating income if not mitigated.
